Navigation Links
OrPro Therapeutics Receives US Patent Covering Novel Enzymatic Treatment for Cystic Fibrosis
Date:10/27/2015

SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- OrPro Therapeutics, Inc. announced today that the US Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,168,290 covering the ability of Theradux™ (recombinant modified human thioredoxin-1) to improve the viscoelastic properties of mucus secretions in patients with diseases characterized by excessively viscous or cohesive mucus or sputum, such as cystic fibrosis (CF) and other obstructive lung diseases.

In CF patients, mucus is unable to perform its essential function of clearing the lungs, leading to life-threatening chronic infection and inflammation. Theradux is an inhaled, non-systemic version of the naturally-secreted enzyme thioredoxin which helps to prevent excess molecular bonds from forming within the mucus layer. The demonstrated deficiency of this activity in patients with CF may be a key driver for progressive impairment of lung function.

Treatment with nebulized Theradux, which relaxes abnormally stiffened mucus, is anticipated to help restore mucus transport and clearance in the majority of CF patients. Theradux is expected to work both alone and in concert with approved and in-development Cystic Fibrosis Transmembrane Regulator (CFTR) modifier therapies to further slow the progression to lung failure, a critical unmet need in CF.

The broad claims issued today are the first in a new US and international patent family owned by OrPro that extends coverage to at least 2034 and adds to the company's existing in-licensed patent estate surrounding thioredoxin's ability to modify the viscoelasticity of mucus. OrPro is the exclusive licensee of issued and pending thioredoxin-related patents from its research partner National Jewish Health (Denver, CO), the leading US respiratory hospital.

"The wide scope of this patent reflects the novelty of our research findings and their importance in creating new treatment options for patients in need," said Peter B. Heifetz, Ph.D., president and CEO of OrPro.

At the recent 2015 North American Cystic Fibrosis Foundation Conference, OrPro presented results from in-vitro and in-vivo studies of Theradux funded by the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH/NHLBI) and the Cystic Fibrosis Foundation. This work confirmed the unique mucus-binding mechanism of Theradux and demonstrated a lack of toxicity and inflammation in pre-clinical, acute aerosol-inhalation studies. OrPro will also present these data at the upcoming NIH/NHLBI Innovation Conference – West on November 17, 2015 in Irvine, CA.

About Cystic Fibrosis

CF is characterized by overproduction of thickened mucus resulting in impaired lung function, chronic infection and premature death, and is the most common inherited lethal disease among populations of primarily Northern European descent. CF affects more than 30,000 individuals in the United States and nearly 80,000 worldwide. While the life expectancy of CF patients has continued to increase, from 18 years prior to 1980 to nearly 40 years today, there is still an urgent need for improved therapies to further extend life expectancy and enhance quality of life.

About OrPro

OrPro Therapeutics, Inc. (San Diego, CA) is developing a therapeutic platform based on thioredoxin, a human protein disulfide-reducing enzyme with unique mucus-normalizing, anti-inflammatory and anti-infective properties. OrPro's lead candidate Theradux (ORP-100) is a new inhaled treatment designed to treat cystic fibrosis (CF) and other obstructive diseases characterized by thickened, stiff and adhesive mucus. The company's research facilities are located on the Torrey Pines mesa at the 40,000 square foot JLABS facility at Janssen Research & Development's La Jolla-based West Coast Research Center. JLABS is a "no strings attached" model that provides core research labs hosting specialized capital equipment, shared administrative areas and individual bench, wet lab and office modules.

Contact:

Michele Parisi
FHC, Inc.
(925) 429-1850
mparisi@forwardhealthinc.com 

 


'/>"/>
SOURCE OrPro Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as ... that Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual ... that was started in 2003 to salute young achievers in Southwest Florida who have ...
(Date:9/21/2017)... ... ... SABRE is raising awareness about personal safety with a Chicago Transit Authority ... The Chicago, Illinois, based self-defense brand has been waiting for an opportunity like this ... their personal safety into their own hands. , The ads focus on their diverse ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up with ... In the competitive world of drug and device marketing and promotion, drug and ... rules. , The FDA has issued two draft guidances that are the closest ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... or exercise more try taking a more holistic approach and use natural alternatives ... Amazon essential oil collection is certified USDA guaranteeing that, the new line of ...
Breaking Medicine News(10 mins):